Aslan Pharmaceuticals has entered into an agreement with Bristol-Myers Squibb to develop an investigational small molecule inhibitor of MET receptor tyrosine kinase, BMS-777607, for treating solid tumours.

Aslan will have rights to develop and market BMS-777607 in Australia, China, Korea, Taiwan and other Asian countries, while Bristol-Myers Squibb will retain rights in the rest of the countries.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Under a pre-agreed development programme, the two parties will develop BMS-777607 against gastric cancer and lung cancer.

Francis Cuss, senior vice-president of research at Bristol-Myers Squibb, said that the partnership will work to produce high-quality data that may be used to further develop and commercialise the medicine worldwide.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now